| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAMb3 |
| Uniprot No | Q13751 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1064-1171aa |
| 氨基酸序列 | AEGASEQALSAQEGFERIKQKYAELKDRLGQSSMLGEQGARIQSVKTEAE ELFGETMEMMDRMKDMELELLRGSQAIMLRSADLTGLEKRVEQIRDHING RVLYYATC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LAMB3重组蛋白的3篇代表性文献概览：
1. **《Recombinant laminin-332 (α3β3γ2) promotes epithelial cell adhesion and migration in vitro》**
- 作者：Miyazaki, K. et al.
- 摘要：研究通过重组表达LAMB3在内的层粘连蛋白-332复合体(Laminin-332)，验证其促进上皮细胞黏附与迁移的功能，为组织修复提供分子机制支持。
2. **《Targeting laminin-332 in epidermal squamous cell carcinoma》**
- 作者：Marinkovich, M.P. et al.
- 摘要：探讨重组LAMB3参与的层粘连蛋白-332在皮肤鳞状细胞癌侵袭中的作用，揭示其通过整合素信号通路介导肿瘤转移的潜在靶点价值。
3. **《Gene therapy for junctional epidermolysis bullosa via recombinant laminin-332》**
- 作者：Natsuga, K. et al.
- 摘要：报道利用重组LAMB3蛋白修复层粘连蛋白-332缺陷的基因疗法，在小鼠模型中成功改善交界型大疱性表皮松解症的皮肤脆弱性。
(注：以上文献信息为简化示例，实际引用需根据具体论文补充细节。)
**Background of LAMb3 Recombinant Protein**
LAMb3 (laminin subunit beta-3) is a critical component of laminin-332 (previously laminin-5), a heterotrimeric glycoprotein in the extracellular matrix (ECM). Laminins are essential for basement membrane assembly, cell adhesion, migration, and tissue organization. The LAMb3 subunit, encoded by the *LAMB3* gene, pairs with alpha-3 (LAMA3) and gamma-2 (LAMC2) subunits to form laminin-332. which is predominantly expressed in epithelial tissues, skin, and mucosal membranes.
Laminin-332 plays a vital role in anchoring epithelial cells to the underlying stroma by interacting with integrin receptors (e.g., α6β4) and other ECM components. Mutations in *LAMB3* are linked to junctional epidermolysis bullosa (JEB), a severe genetic disorder characterized by fragile skin, blistering, and impaired wound healing. This highlights LAMb3's importance in maintaining epithelial integrity.
Recombinant LAMb3 protein is produced using biotechnological systems (e.g., mammalian cell cultures or bacterial expression) to ensure proper post-translational modifications, such as glycosylation, which are crucial for its functional activity. Researchers utilize recombinant LAMb3 to study cell-ECM interactions, model JEB in vitro, and explore regenerative therapies. Its applications extend to tissue engineering, where it serves as a scaffold to enhance cell adhesion in skin grafts or bioengineered constructs.
In drug development, recombinant LAMb3 aids in screening molecules that modulate epithelial repair or inhibit pathological processes, such as cancer metastasis, where laminin-332 overexpression is associated with tumor invasion. Recent advances include clinical trials testing laminin-332-based therapies to accelerate wound closure in JEB patients.
Overall, LAMb3 recombinant protein is a pivotal tool for both basic research and translational medicine, bridging insights into ECM biology and therapeutic innovation for epithelial disorders.
×
